Department of Critical Care Medicine, University of Calgary, Calgary, Alberta, Canada.
Department of medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada.
Hepatol Commun. 2024 Oct 30;8(11). doi: 10.1097/HC9.0000000000000575. eCollection 2024 Nov 1.
Acute liver failure (ALF) is a rare condition leading to morbidity and mortality. Liver transplantation (LT) is often required, but patients are not always listed for LT. There is a lack of data regarding outcomes in these patients. Our aim is to describe outcomes of patients with ALF not listed for LT and to compare this with those listed for LT.
Retrospective analysis of all nonlisted patients with ALF enrolled in the Acute Liver Failure Study Group (ALFSG) registry between 1998 and 2018. The primary outcome was 21-day mortality. Multivariable logistic regression was done to identify factors associated with 21-day mortality. The comparison was then made with patients with ALF listed for LT.
A total of 1672 patients with ALF were not listed for LT. The median age was 41 (IQR: 30-54). Three hundred seventy-one (28.9%) patients were too sick to list. The most common etiology was acetaminophen toxicity (54.8%). Five hundred fifty-eight (35.7%) patients died at 21 days. After adjusting for relevant covariates, King's College Criteria (adjusted odds ratio: 3.17, CI 2.23-4.51), mechanical ventilation (adjusted odds ratio: 1.53, CI: 1.01-2.33), and vasopressors (adjusted odds ratio: 2.10, CI: 1.43-3.08) (p < 0.05 for all) were independently associated with 21-day mortality. Compared to listed patients, nonlisted patients had higher mortality (35.7% vs. 24.3%). Patients deemed not sick enough had greater than 95% survival, while those deemed too sick still had >30% survival.
Despite no LT, the majority of patients were alive at 21 days. Survival was lower in nonlisted patients. Clinicians are more accurate in deeming patients not sick enough to require LT as opposed to deeming patients too sick to survive.
急性肝衰竭(ALF)是一种罕见的疾病,会导致发病率和死亡率。肝移植(LT)通常是必需的,但并非所有患者都接受 LT 治疗。关于这些患者的预后数据有限。我们的目的是描述未接受 LT 治疗的 ALF 患者的结局,并将其与接受 LT 治疗的患者进行比较。
对 1998 年至 2018 年间在急性肝衰竭研究组(ALFSG)登记处登记的所有未接受 LT 治疗的非名单患者进行回顾性分析。主要结局为 21 天死亡率。进行多变量逻辑回归以确定与 21 天死亡率相关的因素。然后将其与接受 LT 治疗的 ALF 患者进行比较。
共有 1672 例 ALF 患者未接受 LT 治疗。中位年龄为 41(IQR:30-54)。371 例(28.9%)患者因病情过重而无法接受 LT。最常见的病因是对乙酰氨基酚中毒(54.8%)。558 例(35.7%)患者在 21 天内死亡。在调整了相关协变量后,King's College 标准(调整后的优势比:3.17,95%CI:2.23-4.51)、机械通气(调整后的优势比:1.53,95%CI:1.01-2.33)和血管加压药(调整后的优势比:2.10,95%CI:1.43-3.08)(p<0.05)与 21 天死亡率独立相关。与名单上的患者相比,未列入名单的患者死亡率更高(35.7%比 24.3%)。被认为病情不够严重的患者生存率超过 95%,而被认为病情过于严重的患者生存率仍超过 30%。
尽管未接受 LT 治疗,但大多数患者在 21 天内仍存活。未列入名单的患者生存率较低。临床医生在判断患者是否不需要 LT 治疗而不是判断患者是否病情过重而无法生存方面更为准确。